• Sun. Oct 24th, 2021

Pfizer and Moderna vaccine, second dose after 42 days: Cts indication


May 5, 2021

An interval of 42 days is recommended in Italy between the first and second dose of Pfizer and Moderna vaccines. The leaflet of the two mRna vaccines provides respectively 21 and 28 days of waiting between the two doses. The new indication of the Scientific Technical Committee for the coronavirus emergency is contained in the opinion attached to a circular from the Ministry of Health. Object of the document, signed by the Director General for Prevention, Giovanni Rezza: ‘Transmission of the opinion of the CTS regarding the extension of the interval between the two doses of the mRna vaccines and the second dose of the Vaxzevria vaccine’. Read also The ‘leaflet’ of the two vaccines provides intervals of 3 and 4 weeks between administrations. The new indications serve to guarantee the protection of the vaccine, with the first dose, to subjects at risk who are still without a ‘screen’. “In relation to the evolution in the conduct of the vaccination campaign against Sars-CoV-2 – we read in an extract of the minutes of the Committee, dated 30 April – the CTS points out that a significant number of unvaccinated subjects remains who, due to connotations data or concomitant pathologies, they are at high risk of developing forms of Covid-19 markedly serious or even fatal. Based on this consideration, even in the face of registration studies that indicate how the interval between the first and second dose of vaccines to Rna (Pfizer / BioNtech and Moderna) of both 21 and 28 days respectively, it is recommended to prolong the administration of the second dose in the sixth week after the first dose “. Lengthening the interval between the first and second dose would have no contraindications:” This consideration – the experts motivate – finds its rationale in the following observations: the administration of the second dose within 42 days from the first does not it affects the effectiveness of the immune response; the first administration of both RNA vaccines already confers effective protection against the development of serious Covid-19 pathology in a high percentage of cases (greater than 80%); in a scenario in which there is still a need in the country to cover a high number of subjects at risk of developing serious or even fatal forms of Covid-19, there are conditions in which it is appropriate to give priority to public health strategies that make it possible to cover from the risk as many subjects as possible in the shortest possible time “.” The opinion – specifies the CTS – may in the future be supported by further epidemiological analysis on: lethality by age group, infected by age group (current data of new infections), estimate of the infected also modeled with respect to the data of the prevalence study “.